A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP 1 Mutations
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Sapanisertib (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2018.
- 10 Oct 2016 Status changed from not yet recruiting to recruiting.
- 21 Apr 2015 New trial record